Journal article · 2023 · Open access
Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study
Frontiers in Pharmacology, 14, 1165711 · Published 30 October 2023 · DOI 10.3389/fphar.2023.1165711
In brief
“Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study” is a 2023 journal article by Yun‐Kyoung Song and 4 co-authors, published in Frontiers in Pharmacology. OpenAlex counts 17 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Pharmacology.
- Citations
- 17
- Most cited in
- 2026 (8)
- Field-weighted impact
- 2.84
- References
- 34
- Authors
- 5
Abstract
Objectives: Despite the ethnic differences in cardiovascular (CV) risks and recent increase in the prescription of Janus kinase (JAK) inhibitors, limited evidence is available for their CV outcomes in Asian patients with rheumatoid arthritis (RA). We aimed to compare the major adverse CV events (MACEs) of JAK inhibitors to those of biologic disease-modifying antirheumatic drugs (bDMARDs) in Korean patients with RA without baseline CV disease (CVD). Methods: In a nationwide retrospective cohort study, patients newly diagnosed with RA without a history of CVD between 2013 and 2018 were identified using the National Health Insurance Service database. The cohort was followed up until the end of 2019 for the development of MACEs. Hazard ratios (HRs) for MACEs such as myocardial infarction, stroke, coronary revascularization, or all-cause death, were estimated using Cox proportional hazard regression in a propensity score-matched cohort. Results: In total, 4,230 matched patients with RA were included (846 JAK inhibitor users and 3,384 bDMARD users). The crude incidence rate (95% confidence intervals, CI) per 100 patient-years for MACEs was 0.83 (0.31–1.81) and 0.74 (0.53–1.02) in the JAK inhibitor and bDMARD groups, respectively. The risk of MACEs was not significantly different between JAK inhibitor and bDMARD users with an adjusted HR (95% CI) of 1.28 (0.53–3.11). There were no significant differences in the risk of MACEs between JAK inhibitors and bDMARDs in each subgroup according to the types of bDMARDs, age, sex, Charlson comorbidity index score, and comorbidities. Conclusion: Compared to bDMARDs, JAK inhibitors were not associated with the occurrence of MACEs in Korean patients with RA without a history of CVD.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Song, Y., Lee, G., Hwang, J., Kim, J., & Kwon, J. (2023). Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study. Frontiers in Pharmacology, 14, 1165711. https://doi.org/10.3389/fphar.2023.1165711
MLA 9
Song, Yun‐Kyoung, et al. “Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study.” Frontiers in Pharmacology, vol. 14, 2023, p. 1165711. https://doi.org/10.3389/fphar.2023.1165711.
Chicago
Song, Yun‐Kyoung, Gaeun Lee, Jinseub Hwang, JW Kim, and Jin‐Won Kwon. 2023. “Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study.” Frontiers in Pharmacology 14: 1165711. https://doi.org/10.3389/fphar.2023.1165711.
Harvard
Song, Y. et al. (2023) ‘Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study’, Frontiers in Pharmacology, 14, p. 1165711. doi:10.3389/fphar.2023.1165711.
IEEE
Y. Song, G. Lee, J. Hwang, J. Kim, and J. Kwon, “Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study,” Frontiers in Pharmacology, vol. 14, p. 1165711, 2023, doi: 10.3389/fphar.2023.1165711.
BibTeX
@article{song2023cardiovascular,
title = {{Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study}},
author = {Song, Yun‐Kyoung and Lee, Gaeun and Hwang, Jinseub and Kim, JW and Kwon, Jin‐Won},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
pages = {1165711},
doi = {10.3389/fphar.2023.1165711},
url = {https://doi.org/10.3389/fphar.2023.1165711}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 1 | |
| 2024 | 3 | |
| 2025 | 5 | |
| 2026 | 8 |
Its field-weighted citation impact is 2.84: it has been cited 2.84 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- JAK inhibitors
- biologic DMARDs
- rheumatoid arthritis
- major adverse cardiovascular events
- cardiovascular risk
- Korean patients
- myocardial infarction
- stroke
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Song, Y., Lee, G., Hwang, J., Kim, J., & Kwon, J. (2023). Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study. Frontiers in Pharmacology, 14, 1165711. https://doi.org/10.3389/fphar.2023.1165711
How many times has this paper been cited?
17 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Frontiers in Pharmacology: sign in and open the PDF from this page.
Who wrote this paper?
Yun‐Kyoung Song, Gaeun Lee, Jinseub Hwang, JW Kim, Jin‐Won Kwon.
What is the DOI of this paper?
10.3389/fphar.2023.1165711, permanently at https://doi.org/10.3389/fphar.2023.1165711. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.